Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats

Endocrinology (United States)

Volumn 156, Issue 10, 2015, Pages 3559-3569

  Romaní Pérez, Marina ^a,b   Outeiriño Iglesias, Verónica ^a,b   Moya, Christian M ^c   Santisteban, Pilar ^c   González Matías, Lucas C ^a,b   Vigo, Eva ^a,b   Mallo, Federico ^a,b  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY OF VIGO   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; LIRAGLUTIDE; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NKX2.1; UNCLASSIFIED DRUG; DIPEPTIDYL CARBOXYPEPTIDASE; SURFACTANT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GLYCEMIC CONTROL; HEART RIGHT VENTRICLE HYPERTROPHY; INSULIN DEPENDENT DIABETES MELLITUS; LUNG; LUNG FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANGIOGRAPHY; ANIMAL; CHEMISTRY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANGIOGRAPHY; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPERTROPHY, RIGHT VENTRICULAR; INSULIN; LIRAGLUTIDE; LUNG; MALE; PEPTIDYL-DIPEPTIDASE A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN B; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

EID: 84943643452     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1685     Document Type: Article

References (56)

1. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987; 79(2):616-619.
2. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing β-cells of the rat endocrine pancreas. Diabetes. 1997;46(5):785-791.
3. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968-2978.
4. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(5):262-269.
5. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379(6560): 69-72.
6. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996;81(1):327-332.
7. Villanueva-Peñacarrillo ML, Márquez L, González N, Daz-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res. 2001;33:73-77.
8. Gil-Lozano M, Pérez-Tilve D, Alvarez-Crespo M, et al. GLP-1(7-36)-amide and exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology. 2010;151(6):2629-2640.
9. Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53(10):2256-2263.
10. Liu H, Dear AE, Knudsen LB, SimpsonRW.Along acting glucagonlike peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009;201(1):59-66.
11. Roman-Pérez M, Outeiriño-Iglesias V, Gil-Lozano M, González-Matas LC, Mallo F, Vigo E. Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats. Endocrinology. 2013;154(3):1144-1155.
12. Benito E, Blazquez E, Bosch MA. Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3',5'-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes. Endocrinology. 1998;139(5): 2363-2368.
13. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004;27(3): 752-757.
14. Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration. 1999;66:14-19.
15. Kida K, Utsuyama M, Takizawa T, ThurlbeckWM.Changes in the morphologic features and elasticity caused by streptozotocin-induced diabetes mellitus in growing rats. Am Rev Respir Dis. 1983; 128(1):125-131.
16. Guazzi M., Brambilla R, De Vita S, Guazzi MD. Diabetes worsens pulmonary diffusion in heart failure, and insulin counteracts this effect. Am J Respir Crit Care Med. 2002;166:978-982.
17. Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. Chest. 2005;128(5):3568-3571.
18. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2008;44(1):14-30.
19. Fiordaliso F, Li B, Latini R, et al. Myocyte death in streptozotocininduced diabetes in rats in angiotensin II-dependent. Lab Invest. 2000;80(4):513-527.
20. Patel VB, Bodiga S, Basu R, et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res. 2012;110(10):1322-1335.
21. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747-803.
22. Wagenaar GT, Laghmani el H, Fidder M, et al. Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopul-monary disease in rats with neonatal hyperoxia-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2013;305(5):L341-L351.
23. Kato H, Suzuki H, Tajima S, et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J. Hypertens. 1991;9:17-22.
24. Shatanawi A, Romero MJ, Iddings JA, et al. Angiotensin II- induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen activated protein kinase/arginase pathway. Am J Physiol. 2011;300(5):C1181-C1192.
25. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292(1):C82-C97.
26. Seeger W, Günther A, Walmrath HD, Grimminger F, Lasch HG. Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects. Clin Investig. 1993;71(3): 177-190.
27. Fernández-Real JM, Chico B, Shiratori M, Nara Y, Takahashi H, Ricart W. Circulating surfactant protein A (SP-A), a marker of lung injury, is associated with insulin resistance. Diabetes Care. 2008; 31(5):958-963.
28. Fernández-Real JM, Valdés S, Manco M, et al. Surfactant protein D, a marker of lung innate immunity, is positively associated with insulin sensitivity. Diabetes Care. 2010;33(4):847-853.
29. Vara E, Arias-Daz J, Garcia C, Balibrea JL, Blázquez E. Glucagon-like peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes. Am J Respir Crit Care Med. 2001;163(4):840-846.
30. de Lemos JA, McGuire DK, DraznerMH.B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316-322.
31. Condurache AP, Aach T. Vessel segmentation in angiograms using hysteresis thresholding. Proceedings of the 9th International Association of Pattern Recognition Conference on Machine Vision Applications, Tsukuba Science City, Japan, 2005:269-272.
32. Givvimani S, Sen U, Tyagi N, Munjal C, Tyagi SC. X-ray imaging of differential vascular density in MMP-9-/-, PAR-1-/-, hyperhomocysteinemic (CBS-/-) and diabetic (Ins2-/-) mice. Arch Physiol Biochem. 2011;117(1):1-7.
33. Bruno MD, Bohinski RJ, Huelsman KM, Whitsett JA, Korfhagen TR. Lung cell-specific expression of the murine surfactant proteinA (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1. J Biol Chem. 1995;270(12): 6531-6536.
34. Bohinski RJ, Di Lauro R, Whitsett JA. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol Cell Biol. 1994;14(9):5671-5681.
35. Bolt RJ, van Weissenbruch MM, Lafeber HN, Delemarre-van de Waal HA. Glucocorticoids and lung development in the fetus and preterm infant. Pediatr Pulmonol. 2001;32(1):76-91.
36. Chan O, Inouye K, Vranic M, Matthews SG. Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetes is associated with reduced stress responsiveness and decreased pituitary and adrenal sensitivity. Endocrinology. 2002;143(5): 1761-1768.
37. Foster DJ, Ravikumar P, Bellotto DJ, Unger RH, Hsia CC. Fatty diabetic lung: altered alveolar structure and surfactant protein expression. Am J Physiol Lung Cell Mol Physiol. 2010;298:L392-L403.
38. Ofulue AF, Kida K, Thurlbeck WM. Experimental diabetes and the lung. I. Changes in growth, morphometry, and biochemistry. Am Rev Respir Dis. 1988;137(1):162-166.
39. Uhal BD, Longmore WJ. Altered phospholipid biosynthesis in type II pneumocytes isolated from streptozotocin-diabetic rats. Biochim Biophys Acta. 1986;878(2):266-272.
40. Brown LA, Longmore WJ. Altered phospholipid secretion in type II pneumocytes isolated from streptozotocin-diabetic rats. Biochim Biophys Acta. 1986;878(2):258-265.
41. OdomMJ, Snyder JM, Mendelson CR. Adenosine 3',5'-monophosphate analogs and β-adrenergic agonists induce the synthesis of the major surfactant apoprotein in human fetal lung in vitro. Endocrinology. 1987;121(3):1155-1163.
42. Liley HG, White RT, Warr RG, Benson BJ, Hawgood S, Ballard PL. Regulation of messenger RNAs for the hydrophobic surfactant proteins in human lung. J Clin Invest. 1989;83(4):1191-1197.
43. Sugahara K, Iyama K, Sano K, Morioka T. Differential expressions of surfactant protein SP-A, SP-B, and SP-C mRNAs in rats with streptozotocin-induced diabetes demonstrated by in situ hybridization. Am J Respir Cell Mol Biol. 1994;11(4):397-404.
44. Rayani HH, Gewolb IH, Floros J. Glucose decreases steady state mRNA content of hydrophobic surfactant proteins B and C in fetal rat lung explants. Exp Lung Res. 1999;25(1):69-79.
45. Sugahara K, Iyama K, Sano K, Morioka T. Overexpression of pulmonary surfactant apoprotein A mRNA in alveolar type II cells and nonciliated bronchiolar (Clara) epithelial cells in streptozotocininduced diabetic rats demonstrated by in situ hybridization. Am J Respir Cell Mol Biol. 1992;6(3):307-314.
46. Viby NE, Isidor MS, Buggeskov KB, Poulsen SS, Hansen JB, Kissow H. Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice. Endocrinology. 2013;154(12):4503-4511.
47. Callaerts-Vegh Z, Evans KL, Dudekula N, et al. Effects of acute and chronic administration of β-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA. 2004; 101(14):4948-4953.
48. Nogueiras R, Tovar S, Mitchell SE, et al. Regulation of growth hormone secretagogue receptor gene expression in the arcuate nuclei of the rat by leptin and ghrelin. Diabetes. 2004;53(10):2552-2558.
49. Ferreira AJ, Shenoy V, Yamazato Y, et al. Evidence for angiotensinconverting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179(11):1048-1054.
50. Morrel NW, Upton PD, Kotecha S, et al. Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors. Am J Physiol. 1999;277(3 pt 1):L440-L448.
51. Aras O, Dilsizian V. Targeting tissue angiotensin-converting enzyme for imaging cardiopulmonary fibrosis. Curr Cardiol Rep. 2008; 10(2):128-134.
52. Santos RA, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension. 1992;19(2 suppl):II56 -II61.
53. Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension. 1992; 19:692-696.
54. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012;123(8):487-498.
55. Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18(23):3506-3515.
56. Shenoy V, Qi Y, Katovich MJ, Raizada MK. ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol. 2011;11(2):150-155.